EZH2 and breast cancer: The TIMP-3 suppression in breast cancer cells is mediated by epigenetic silencing mechanisms, including the increased activity of the enhancer of zeste homolog 2 (EZH2) and class I HDACs, which is independent of promoter DNA hypermethylation [166].